Phathom Pharmaceuticals Stock Faces Dilution Pressure Following Equity Raise

Shares of Phathom Pharmaceuticals are experiencing heightened volatility in the wake of a significant capital raise. The company’s recent equity offering, priced at $16.00 per share, has triggered near-term dilution concerns, applying downward pressure on the stock price. The key question for investors is whether this strategic move will ultimately hinder the long-term commercial momentum for its flagship product, Voquezna.

Despite the market’s reaction to the financing, Phathom continues to report solid commercial advancement. Voquezna has surpassed one million prescriptions in the United States. Preliminary figures for the fourth quarter of 2025 indicate net revenues are estimated between $57 million and $58 million, slightly exceeding the consensus estimate of $56.16 million. The company is Read more...